BMY - IPO Update: Metacrine Seeks $85 Million U.S. IPO

Quick Take

Metacrine (MTCR) intends to raise $85 million from the sale of its common stock in an IPO, according to an amended registration statement.

The company is developing treatment candidates for NASH conditions.

MTCR is entering Phase 2 trials and will have significant capital to pursue its treatments for a large and growing disease.

For life science investors with an 18 - 24-month hold time frame, the IPO may be worth considering.

Company & Technology

San Diego, California-based Metacrine was founded to research treatments for NASH (NonAlcoholic SteatoHepatitis), which is a

Read more ...